FDA expands access for Schizophrenia treatment
The FDA has eliminated a longstanding requirement that patients taking clozapine, an antipsychotic used for treatment-resistant schizophrenia, to submit blood test results before their prescriptions can be filled.
The FDA has eliminated a longstanding requirement that patients taking clozapine, an antipsychotic used for treatment-resistant schizophrenia, to submit blood test results before their prescriptions can be filled.
